Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
PHILADELPHIA, Jan. 03, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief executive officer, is presenting at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, at 11:30 a.m. PST, at the Westin St. Francis Hotel, in San Francisco, California.
A webcast of Marrazzo’s presentation will be available live on www.sparktx.com on the "Events" section of the Investors page. A replay of the presentation will be available on the website for 90 days following the conference. To access his full presentation slide deck, please visit "Investor Presentations" on the Investors page.
In addition, Dan Faga, chief business officer, will participate in a panel discussion on “The coming of age of gene therapy and gene editing,” during the Biotech Showcase on Tuesday, Jan. 10, from 8-9 a.m. PST, at the Hilton San Francisco Union Square.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001, in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer (which also has received both breakthrough therapy and orphan product designations) and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Spark Therapeutics Corporate Contacts: Stephen W. Webster Chief Financial Officer Daniel Faga Chief Business Officer (855) SPARKTX (1-855-772-7589) Media Contact: Dan Quinn Ten Bridge Communication (781) 475-7974 [email protected]
